Oscar Health is trading at $33.76, down 4.06%; available evidence points to broad market pressure rather than a negative company-specific earnings catalyst.
- Q3 revenue was $5.14 billion and diluted EPS was $0.49; results beat estimates, and the company raised its full-year outlook.
- The S&P 500 was down 4.12%, the Nasdaq 5.30%, and the Dow 3.35%.
- Volume data was not provided.